Valuation: DiaSorin S.p.A.

Market Cap 3.65B 4.17B 3.36B 3.11B 5.9B 398B 6B 40.2B 15.79B 196B 15.66B 15.32B 674B P/E 2026 *
20x
P/E 2027 * 17.6x
Enterprise Value 4.32B 4.94B 3.99B 3.68B 6.98B 471B 7.1B 47.61B 18.7B 232B 18.55B 18.14B 798B EV / Sales 2026 *
3.52x
EV / Sales 2027 * 3.21x
Free-Float
37.17%
Yield 2026 *
1.9%
Yield 2027 * 1.98%
1 day+1.11%
1 week-1.40%
Current month+2.10%
1 month+2.79%
3 months+12.93%
6 months-7.59%
Current year+0.64%
1 week 66.1
Extreme 66.1
71.4
1 month 63.02
Extreme 63.02
71.4
Current year 51.14
Extreme 51.14
77.58
1 year 51.14
Extreme 51.14
92.36
3 years 51.14
Extreme 51.14
112.1
5 years 51.14
Extreme 51.14
208.7
10 years 30.74
Extreme 30.7396
211.8
Manager TitleAgeSince
Chief Executive Officer 60 26/03/2007
Director of Finance/CFO - 01/01/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 60 28/04/2016
Director/Board Member 63 26/03/2007
Chairman 57 29/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%-1.40% - - 4.17B
-2.46%-4.72%+218.51%+323.86% 21.22B
+0.50%+0.65%-41.47%-25.47% 9.41B
-0.33%-3.87%+29.92%+25.91% 6.88B
-0.86%+9.54%+233.83%-28.23% 5.42B
+3.74%-1.63%-21.04%-27.79% 5.05B
-4.92%-7.16%-35.91% - 4.8B
+0.75%-11.50%+60.48%+70.78% 3.64B
+0.62%-0.77%-18.68%-43.38% 2.59B
+3.72%+1.08%-33.53%+200.90% 1.61B
Average +0.17%-1.76%+43.57%+62.07% 6.74B
Weighted average by Cap. -0.71%-1.94%+91.70%+125.15%

Financials

2026 *2027 *
Net sales 1.23B 1.4B 1.13B 1.04B 1.98B 134B 2.01B 13.51B 5.31B 65.85B 5.26B 5.15B 226B 1.3B 1.49B 1.2B 1.11B 2.11B 142B 2.14B 14.37B 5.64B 70.04B 5.6B 5.48B 241B
Net income 182M 208M 168M 155M 295M 19.88B 300M 2.01B 789M 9.79B 783M 766M 33.67B 205M 235M 189M 175M 332M 22.37B 337M 2.26B 888M 11.02B 881M 861M 37.88B
Net Debt 673M 769M 621M 573M 1.09B 73.37B 1.11B 7.42B 2.91B 36.15B 2.89B 2.83B 124B 542M 620M 500M 462M 876M 59.09B 891M 5.97B 2.35B 29.11B 2.33B 2.28B 100B
Logo DiaSorin S.p.A.
DiaSorin S.p.A. specializes in the development, manufacturing and marketing of in vitro diagnostic reagents. The products are used in treating infectious and viral diseases, thyroid pathologies, cancer, etc. At the end of 2025, the group had 9 production sites located in Italy, the United States (4), Canada, Germany, the United Kingdom and Chine. Net sales are distributed geographically as follows: Italy (15.2%), Europe (24.9%), North America (51.8%), and other (8.1%).
Employees
3,242
Date Price Change Volume
13/07/26 69.18 +0.86% 0
10/07/26 €68.82 -1.26% 18,255
09/07/26 €69.70 +4.69% 12,775
08/07/26 €66.58 -0.63% 17,577
07/07/26 €67.00 -4.50% 31,246
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
68.82EUR
Average target price
70.16EUR
Spread / Average Target
+1.95%

Quarterly revenue - Rate of surprise